Bio-Rad Q4 revenue down 7.2% to $733M; GAAP loss $52.59/sh, non-GAAP EPS $3.21; 2022 outlook 1-2% growth

BIO-RAD LABORATORIES, INC.

2021-FY EPS reported $140.56 revenue$2,922,500,000

Q4 2021 sales $732.8M (-7.2% YoY); Life Science sales down 23.8% on lower COVID-related qPCR demand.
GAAP net loss $1,573.7M ($52.59 loss per diluted share) vs net income $839.1M in Q4 2020, impacted by Sartorius AG fair value changes.
Non-GAAP net income $97.0M ($3.21 per share) vs $121.0M ($4.01) in Q4 2020.
Full year 2021 sales $2,922.5M (+14.8% reported); core revenue ex-COVID up 17.0% currency-neutral.
2022 guidance: non-GAAP currency-neutral revenue growth 1-2%, non-GAAP operating margin ~19.0%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.